miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway

被引:50
|
作者
Wan, Jun [1 ]
Ling, Xiean [1 ]
Peng, Bin [1 ]
Ding, Guanggui [1 ]
机构
[1] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Thorac Surg, 1017 DongMen North Rd, Shenzhen 518020, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
miR-142-5p; CD4(+) T cells; NSCLC; PD-L1; PTEN; ANTITUMOR; GENE; DIFFERENTIATION; POLYMORPHISMS; CARCINOMA; MODEL;
D O I
10.3892/or.2018.6439
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to evaluate the function of microRNA (miR)-142-5p on cancer immunity to induce apoptosis in human non-small cell lung cancer (NSCLC) and its mechanism. miR-142-5p expression was upregulated, and CD4(+) T cell levels were reduced in patients with NSCLC. Overexpression of miR-142-5p expression inhibited the cancer effects of CD4(+) T cells on NSCLC cell lines, and downregulation of miR-142-5p increased the cancer effects of CD4(+) T cells on NSCLC cell lines, compared with the control group. In addition, we found that overexpression of miR-142-5p suppressed PTEN protein expression and induced PI3K, p-Akt and PD-L1 protein expression in an in vitro model of NSCLC. Downregulation of miR-142-5p induced PTEN and PD-L1 protein expression and suppressed PI3K and p-Akt and protein expression in an in vitro model of NSCLC. The suppression of PD-L1 reduced the cancer effects of CD4(+) T cells on NSCLC cell lines following miR-142-5p downregulation. The inhibition of PTEN also reduced the cancer effects of CD4(+) T cells on NSCLC cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4(+) T cells in human NSCLC through PD-L1 expression via the PTEN pathway.
引用
收藏
页码:272 / 282
页数:11
相关论文
共 50 条
  • [21] PD-L1 Expression as a Prognostic Marker for Non-Small Cell Lung Cancer in Distinct Mutational Status
    Trachu, N.
    Oranratnachai, S.
    Iemwimangsa, N.
    Incharoen, P.
    Detarkom, S.
    Sanvarinda, P.
    Chantratita, W.
    Reungwetwattana, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S739 - S740
  • [22] Significance of the Expression of PD-L1/PD-1 by Tumoral and Immune Cells in Non-Small Cell Lung Cancer.
    Ortiz-Villalon, C.
    De Petris, L.
    Kis, L.
    Yoshikawa, A.
    Ngoc, H.
    Roden, A.
    Fukuoka, J.
    Montero, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S948 - S948
  • [23] The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer
    Kim, Gun-Jik
    Lee, Jae-Ho
    Park, Won-Jin
    Lee, Hye-Won
    Hwang, Il-Seon
    Lee, Deok Heon
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2019, 49 (03) : 317 - 323
  • [24] Anticancer Effects of 6-Gingerol through Downregulating Iron Transport and PD-L1 Expression in Non-Small Cell Lung Cancer Cells
    Kang, Dong Young
    Park, Sanghyeon
    Song, Kyoung Seob
    Bae, Se Won
    Lee, Jeong-Sang
    Jang, Kyoung-Jin
    Park, Yeong-Min
    Seki, Nobuhiko
    Tanzawa, Shigeru
    CELLS, 2023, 12 (22)
  • [25] Knockdown of lncRNA XIST Suppresses Cell Tumorigenicity in Human Non-Small Cell Lung Cancer by Regulating miR-142-5p/PAX6 Axis
    Jiang, Qingfeng
    Xing, Wenqun
    Cheng, Jinhua
    Yu, Yongkui
    ONCOTARGETS AND THERAPY, 2020, 13 : 4919 - 4929
  • [26] Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer
    Simundza, Ivan
    Krnic, Dragan
    Juricic, Josko
    Benzon, Benjamin
    Simundza, Rina
    Stanicic, Ivan Mario
    Capkun, Vesna
    Vukojevic, Katarina
    Durdov, Merica Glavina
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (08):
  • [27] PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain
    Saez de Gordoa, Karmele
    Lopez, Ingrid
    Marginet, Marta
    Coloma, Berta
    Frigola, Gerard
    Vega, Naiara
    Martinez, Daniel
    Teixido, Cristina
    DIAGNOSTICS, 2021, 11 (08)
  • [28] PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer
    Tsoukalas, Nikolaos
    Kiakou, Maria
    Tsapakidis, Konstantinos
    Tolia, Maria
    Aravantinou-Fatorou, Eleni
    Baxevanos, Panagiotis
    Kyrgias, Georgios
    Theocharis, Stamatios
    JOURNAL OF BUON, 2019, 24 (03): : 883 - 888
  • [29] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
  • [30] MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment
    Song, Nannan
    Li, Peng
    Song, Pingping
    Li, Yintao
    Zhou, Shuping
    Su, Qinghong
    Li, Xiaofan
    Yu, Yong
    Li, Pengfei
    Feng, Meng
    Zhang, Min
    Lin, Wei
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8